Fmr LLC Increases Stock Position in Enhabit, Inc. (NYSE:EHAB)

Fmr LLC lifted its holdings in shares of Enhabit, Inc. (NYSE:EHAB) by 138.4% in the third quarter, HoldingsChannel reports. The firm owned 3,388 shares of the company’s stock after acquiring an additional 1,967 shares during the period. Fmr LLC’s holdings in Enhabit were worth $27,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in Enhabit in the 2nd quarter valued at about $1,941,000. DekaBank Deutsche Girozentrale grew its stake in Enhabit by 52.3% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 518,412 shares of the company’s stock worth $4,306,000 after acquiring an additional 178,000 shares during the period. West Tower Group LLC raised its holdings in Enhabit by 108.8% in the 3rd quarter. West Tower Group LLC now owns 285,142 shares of the company’s stock valued at $2,253,000 after acquiring an additional 148,566 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Enhabit during the second quarter worth $955,000. Finally, GSA Capital Partners LLP increased its stake in Enhabit by 78.4% in the third quarter. GSA Capital Partners LLP now owns 142,012 shares of the company’s stock valued at $1,122,000 after purchasing an additional 62,397 shares during the last quarter.

Insiders Place Their Bets

In other Enhabit news, Director Stuart M. Mcguigan acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were purchased at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the purchase, the director now directly owns 46,810 shares in the company, valued at $412,396.10. The trade was a 47.15 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bolton bought 4,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the purchase, the director now directly owns 98,144 shares of the company’s stock, valued at $852,871.36. The trade was a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.

Enhabit Trading Up 0.1 %

Shares of EHAB stock opened at $7.66 on Thursday. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit, Inc. has a fifty-two week low of $6.85 and a fifty-two week high of $11.74. The firm’s 50 day moving average price is $7.66 and its two-hundred day moving average price is $8.24. The stock has a market cap of $385.18 million, a price-to-earnings ratio of -3.30 and a beta of 1.89.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. The business had revenue of $253.60 million for the quarter, compared to analysts’ expectations of $261.69 million. During the same period last year, the company posted $0.03 earnings per share. On average, analysts anticipate that Enhabit, Inc. will post 0.22 EPS for the current year.

Analyst Ratings Changes

EHAB has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of Enhabit from a “hold” rating to a “buy” rating and upped their price objective for the company from $8.25 to $9.50 in a research note on Monday, December 9th. Leerink Partners reissued a “market perform” rating and set a $8.00 price objective (down from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.75.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.